More than 80 companies currently claim to offer manufacturing related services
Severalbig pharma companies are known to outsource more than half of their clinical-stageoligonucleotide manufacturing operations. Anticipating a sharp rise in demand,oligonucleotide manufacturers are increasingly consolidating their portfolios,building new capabilities and expanding their respective capacities, mostlythrough acquisitions, in order to gain a competitive edge.
To order this 300+ page report, which features 140+ figuresand 190+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/oligonucleotide-synthesis/304.html
The USD 5.8 billion (by 2030) financial opportunitywithin the oligonucleotide synthesis, modification and purification servicesmarket has been analyzed across the following segments:
- Type of manufacturing
§ Custom manufacturing
§ Large-scale manufacturing
- Type of Oligonucleotides manufactured
§ Antisense Oligonucleotides
§ miRNAs
§ shRNAs
§ siRNAs
§ OtherOligonucleotides
- Scale of operation
§ Clinical
§ Commercial
- Purpose of production
§ In-house
§ Outsourced
- Target therapeutic area
§ Autoimmune Disorders
§ Cardiovascular Disorders
§ Genetic Disorders
§ Infectious Diseases
§ Metabolic Disorders
§ Neuromuscular Disorders
§ Oncological Disorders
§ Ophthalmic Disorders
§ Other Therapeutic Areas
- Size of manufacturer
§ Small
§ Mid-sized
§ Large
- Key Geographical Region
§ NorthAmerica
§ Europe
§ Asia-Pacificand Rest of the World
The OligonucleotideSynthesis, Modification and Purification Services Market: Focus on Research,Diagnostic and Therapeutic Applications, 2020-2030 report features the following companies, which weidentified to be key players in this domain:
§ Agilent Technologies
§ Ajinomoto Bio-PharmaServices
§ BioSpring
§ CordenPharma
§ Integrated DNATechnologies
§ Kaneka Eurogentec
§ LGC BiosearchTechnologies
§ Microsynth
§ Nitto Denko Avecia
§ Sigma Aldrich
§ Thermo FisherScientific
§ TrilinkBiotechnologies
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Market Landscape: OligonucleotideManufacturers (Research and Diagnostic Applications)
5. Market Landscape: Oligonucleotide Manufacturers(Therapeutic Applications)
6. Company CompetitivenessAnalysis: Oligonucleotide Manufacturers (Research and Diagnostic Applications)
7. Company CompetitivenessAnalysis: Oligonucleotide Manufacturers (Therapeutic Applications)
8. Company Profiles: Oligonucleotide Manufacturers(Research and Diagnostic Applications)
9. CompanyProfiles: Oligonucleotide Manufacturers (TherapeuticApplications)
10. Partnershipsand Collaborations
11. Recent Expansions
12. ClinicalTrial Analysis
13. Capacity Analysis
14. Demand Analysis
15. Market Sizing andOpportunity Analysis
16. Swot Analysis
17. Survey Analysis
18. Executive Insights
19. ConcludingRemarks
20. Appendix 1:Tabulated Data
21. Appendix 2: Listof Companies and Organizations
To purchase a copy, please visithttps://www.rootsanalysis.com/reports/view_document/oligonucleotide-synthesis/304.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
